Novo Nordisk’s Wegovy Snags Conditional FDA Nod For Fatty Liver Disease

All NewsAugust 18, 2025

FDA approves Novo Nordisk’s Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent